...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >EFFECTIVITY ANALYSIS OF NEUROPROTECTOR (VITAMIN B COMPLEX AND MECOBALAMIN) AS NEUROPATHIC PAIN SUPPORTIVE THERAPY IN ELDERLY WITH TYPE 2 DIABETES MELLITUS
【24h】

EFFECTIVITY ANALYSIS OF NEUROPROTECTOR (VITAMIN B COMPLEX AND MECOBALAMIN) AS NEUROPATHIC PAIN SUPPORTIVE THERAPY IN ELDERLY WITH TYPE 2 DIABETES MELLITUS

机译：神经保护剂（维生素B配合物和甲钴胺素）作为2型糖尿病老年人神经病痛支持疗法的疗效分析

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: Neuroprotector (Vitamin B complex or mecobalamin)is often used as a supportive neuropathic pain therapy. The effectiveness of this drug remains controversial, especially in geriatrics with Type 2 diabetic neuropathy pains. The aim of this study was to compare the diabetes neuropathic pain reduction in elderly with and without neuroprotective supplementation. Method: The study was conducted by prospective cohort design. 132 agings were observed during 4 weeks at Neurology Polyclinic, Sanglah Public Hospital, Denpasar, Bali-Indonesia. Individuals undergoing the first-line neuropathic pain therapy who received neuroprotector supplementation were included in the exposure group (66 individuals), while those not receiving neuroprotective supplementations were included in the nonexposure group (66 individuals). The pain scores were measured by numeric rating scales instruments. The measured outcome was a decrease in diabetic neuropathic pain scores. Result: Both groups showed reduce on pain scores statistically different compared to baseline pain score (p<0.05). The comparison head-to-head on neuroprotector supplementation group showed significantly greater to reduce the pain score compared to nonexposure group (p<0.05). The relative risk of pain score reduction more than 2 units was 1.37 (confidence interval [CI]95%: 1.05-1.80)and the number need to treat was 5 (CI 95%: 3-28) compared to nonexposure group. Conclusion: Individuals who are undergoing the first-line neuropathic pain therapy and getting Vitamin B complex or mecobalamin supplementation had decreased pain intensity better than without supplementation therapy.
机译：目的：神经保护剂（维生素B复合物或甲钴胺）通常用作支持性神经性疼痛疗法。这种药物的有效性仍存在争议，尤其是在患有2型糖尿病神经病变疼痛的老年患者中。这项研究的目的是比较有无神经保护性补充剂的老年人糖尿病性神经痛的减轻。方法：本研究是通过前瞻性队列设计进行的。在印度尼西亚巴厘岛登巴萨Sanglah公立医院神经学综合诊所的4周内观察到132次老化。接受一线神经性疼痛治疗且接受神经保护剂补充的个体被包括在暴露组中（66人），而未接受神经保护性补充剂的个体被包括在非暴露组中（66人）。疼痛分数通过数字评分量表仪器测量。测得的结果是糖尿病性神经痛评分降低。结果：两组患者的疼痛评分降低均较基线疼痛评分有统计学差异（p <0.05）。与非暴露组相比，神经保护剂补充组的头对头比较显示减少疼痛分数明显更大（p <0.05）。与非暴露组相比，疼痛评分降低超过2个单位的相对风险为1.37（置信区间[CI] 95％：1.05-1.80），需要治疗的人数为5（CI 95％：3-28）。结论：正在接受一线神经性疼痛治疗并接受维生素B复合物或补充甲钴胺治疗的患者，其疼痛强度比未进行补充治疗更好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号